Pulmonary langerhans cell histiocytosis by Suri, Harpreet S et al.
REVIEW Open Access
Pulmonary langerhans cell histiocytosis
Harpreet S Suri
1, Eunhee S Yi
2, Gregorz S Nowakowski
3 and Robert Vassallo
1,4*
Abstract
Pulmonary Langerhans Cell Histiocytosis (PLCH) is a relatively uncommon lung disease that generally, but not
invariably, occurs in cigarette smokers. The pathologic hallmark of PLCH is the accumulation of Langerhans and
other inflammatory cells in small airways, resulting in the formation of nodular inflammatory lesions. While the
overwhelming majority of patients are smokers, mechanisms by which smoking induces this disease are not
known, but likely involve a combination of events resulting in enhanced recruitment and activation of Langerhans
cells in small airways. Bronchiolar inflammation may be accompanied by variable lung interstitial and vascular
involvement. While cellular inflammation is prominent in early disease, more advanced stages are characterized by
cystic lung destruction, cicatricial scarring of airways, and pulmonary vascular remodeling. Pulmonary function is
frequently abnormal at presentation. Imaging of the chest with high resolution chest CT scanning may show
characteristic nodular and cystic abnormalities. Lung biopsy is necessary for a definitive diagnosis, although may
not be required in instances were imaging findings are highly characteristic. There is no general consensus
regarding the role of immunosuppressive therapy in smokers with PLCH. All smokers must be counseled on the
importance of smoking cessation, which may result in regression of disease and obviate the need for systemic
immunosuppressive therapy. The prognosis for most patients is relatively good, particularly if longitudinal lung
function testing shows stability. Complications like pneumothoraces and secondary pulmonary hypertension may
shorten life expectancy. Patients with progressive disease may require lung transplantation.
Keywords: Cigarette smoke, Interstitial, Bronchiolitis, Langerhans cells, Pulmonary hypertension
Supported by HL096829-01 and funding from the Flight
Attendant Medical Research Institute.
The histiocytic disorders are rare diseases character-
ized by abnormal infiltration of certain organs by cells
derived from monocyte/macrophage or dendritic cell
lineage [1]. Langerhans Cell Histocytosis (LCH) is a spe-
c i f i ct y p eo fh i s t o c y t i cs y n d r o m ec h a r a c t e r i z e db yi n f i l -
tration of tissues with a specific dendritic cell, the
Langerhans cell [1]. Formally known as histocytosis ×
(or eosinophilic granuloma), it is now apparent that the
“X” cells are Langerhans cells, which may be distin-
guished from other dendritic cells by the presence of
intracellular Birbeck granules and surface expression of
the CD1a receptor [2,3]. Although it is generally agreed
that pathologic Langerhans cells play a central role in
the pathogenesis of LCH, the origins of these cells, their
specific roles in disease development and progression
remain incompletely characterized. LCH may affect an
isolated organ (formerly referred to as eosinophilic gran-
uloma) or may be a multisystemic illness involving sev-
eral sites (formerly referred to as Hand-Shuller-
Christian or Letterer-Siwe disease)[4]. Pulmonary invol-
vement in LCH (which will be referred to as PLCH) is
more common in adults and may be the sole organ
involved, or may be part of multi system disease [5].
Epidemiology and demographic characteristics
PLCH is a rare disease which occurs almost exclusively
in smokers [5,6]. The estimated incidence of LCH is 4-9
cases per million/year in children [7,8]. Precise data
regarding prevalence are not available, but a large series
of hundreds of patients undergoing surgical lung biop-
sies for diffuse lung disease reported PLCH in 4-5% of
all diffuse lung disease biopsies [9]. This is probably an
under estimation as many patients may never undergo
surgical lung biopsy for diagnosis. PLCH predominantly
affects young adults between the ages of 20 to 40 years
[5]. There does not appear to be a gender predilection
[5,10-12]. Although most published series in the English
literature are composed of Caucasian subjects [5,10,11],
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recognized [13]. Few familial cases have been reported
and isolated PLCH is almost always a sporadic illness
[14,15]. Isolated PLCH is very uncommon in children
even though multisystemic LCH is more prevalent than
in the adult population (Table 1).
Cigarette smoking and genetic factors
There are convincing data supporting a causal relation-
ship between cigarette smoke and PLCH in adults
[5,10]. The overwhelming majority (> 90%) of adult
patients who develop PLCH smoke cigarettes or were
exposed to substantial second-hand smoke exposure
[5,10,12]. In children with PLCH, the association with
cigarette smoking is less clear [17], although it has been
reported that the commencement of smoking in teenage
years can precipitate PLCH in young adults with a his-
tory of non-pulmonary childhood LCH [30]. Smoking
cessation may lead to complete or partial remission of
lung lesions [28]. PLCH is characterized by prominent
peribronchial inflammatory changes [31], suggesting
injury of small airways by an inhaled irritant such as
cigarette smoke. All smokers develop increased macro-
phage numbers in the lung: macrophage recruitment
and accumulation around small airways, interstitium
and distal air spaces is a key feature of many smoking-
induced lung diseases, including PLCH [32]. A perplex-
ing and yet unresolved question relates to the observa-
tion that only a very small proportion of smokers
develop PLCH, which implies a role for endogenous
host factors or additional exogenous factors (a second
hit). It is possible that smokers with PLCH develop an
amplified inflammatory response induced by tobacco
smoke (and possibly other factors) that induces activa-
tion of multiple cell types in the lung, including
epithelial and immune cells, resulting in a vicious cycle
of inflammation, tissue injury and tissue remodeling
(Figure 1). Whether failure of endogenous anti-inflam-
matory mechanisms or additional exogenous insults like
viral infections have a role in promoting smoking-
induced PLCH is unknown, and continues to be an
important area of investigation.
Pathogenesis
Dendritic cells are a heterogeneous population of anti-
gen presenting cells, classified into distinct subsets
according to origin, location, surface phenotype, and
functional properties [33,34]. Langerhans cells are a spe-
cific sub-population of dendritic cells, found in the skin
and beneath the epithelium of the tracheobronchial tree
where they serve as a primary line of defense surveying
antigens deposited in the airway following inhalation
[35]. These airway Langerhans cells become activated
following encounter with danger signals, such as Toll-
like receptors expressed by infectious pathogens, or fac-
tors released by injured or necrotic cells in the vicinity
[33,35]. Activation results in a number of changes that
promote antigen presentation and migration to regional
lymphoid tissues where adaptive immune responses are
induced. Langerhans cells also likely play important
roles in mediating tolerance towards harmless inhaled
antigens and are probably very important in preventing
unnecessary airway inflammation to innocuous antigens
deposited in the airway [35,36]. Unraveling the mechan-
isms by which Langerhans cells coordinate airway
immune responses is fundamental to understanding the
pathogenesis of PLCH.
Although evident that cigarette smoke is the most
important factor associated with the development of
PLCH, the effects of smoking on Langerhans cell
Table 1 Contrasting pediatric and adult PLCH
Pediatric PLCH Adult PLCH
Demographic features
Peak age at presentation 1-3 yrs [16] 20-40 yrs [5]
Smoking history Infrequently described [16,17] Reported in > 95% [5,12]
Imaging findings; chest CT
Distribution of abnormalities Frequently involves lower lobes [18] Sparing of bases and costo- phrenic angles is
typical [19-21]
Biological character
Clonality Invariably reported [22-24] Suspect reactive rather than clonal [25]
Clinical Presentation
Single system vs multi-system
presentation
Typically part of multi-system LCH [16] Single system disease in > 80% of patients [5]
Management
Pharmacotherapy with prednisone/
vinblastine
Complete or partial response frequently observed
[26,27]
Insufficient data available; likely limited response
Smoking cessation Limited role as tobacco exposure not involved in
most cases
Main and first line therapy in all adult smokers
[28,29]
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lation of Langerhans cells in the lungs [37-39], and in
patients with PLCH [40,41]. Increased numbers of Lan-
gerhans cells are found in other lung diseases that afflict
smokers, including chronic obstructive pulmonary dis-
ease (COPD), certain interstitial lung diseases, and lung
cancer [41-43]. Increased dendritic cell numbers have
also been reported in the lungs of mice exposed to
cigarette smoke [44]. These observations suggest that
cigarette smoke may alter the normal physiologic turn-
over of dendritic cells in the lung, or possibly may facili-
tate recruitment of Langerhans and dendritic cell
precursors.
Cigarette smoke induces the production of a number
of cytokines that are important for the recruitment,
development, and functional activation of Langerhans
and dendritic cells. Cigarette smoke induces tumor
necrosis factor-alpha (TNFa) production from epithelial
cells and macrophages, which is a critical differentiation
and activation factor for Langerhans cells [45-47]. Cigar-
ette smoke also stimulates granulocyte macrophage col-
ony stimulating factor (GM-CSF) by epithelial cells and
fibroblasts [47]. An immunohistochemical study showed
GM-CSF to be abundantly expressed in the epithelium
of bronchioles affected by inflammatory PLCH lesions
[48]. Cigarette smoke induces the production of trans-
forming growth factor-beta (TGFb) by epithelial cells
[49], which has been shown by immunohistochemical
studies to be over-expressed in PLCH lung biopsies
[50]. TGFb is an essential factor in the development of
Langerhans cells [51], and is an important cytokine
involved in the process that leads to tissue remodeling
by fibrosis and scar formation [52], lesions that are
noted in more advanced stages of disease [31]. Cigarette
smoke also induces the production of dendritic cell che-
mokines like chemokine (C-C motif) ligand 20 (CCL20
or Macrophage Inflammatory Protein-3 alpha), which is
likely derived from an epithelial source [53]. It is highly
plausible that smoking-induced production of TNFa,
GM-CSF, TGFb and CCL20 by cells in the proximity of
lung dendritic and Langerhans cells results in sustained
stimulation of dendritic and Langerhans cells and their
precursors, facilitating their local expansion in peri-
bronchiolar regions. Excessive recruitment of circulating
monocytes (potentially directly induced by cigarette
smoke) is likely to be an essential mechanism by which
expansion of the dendritic and Langerhans cell pool
occurs around small airways [54].
An important link between smoking and PLCH was
recently provided by gene expression studies on Langer-
hans cells extracted from lesional tissue that showed
abundant expression of osteopontin [55], a glycoprotein
with cytokine properties and pro-chemotactic activity
for macrophages, monocytes, Langerhans cells, and den-
dritic cells. Cells obtained by bronchoalveolar lavage of
patients with PLCH spontaneously produced abundant
amounts of osteopontin, which is further induced by
nicotine [56]. Importantly, overexpression of osteopon-
tin in rat lungs induced lesions that were analogous to
those seen in human PLCH, and were characterized by
substantial alveolar and interstitial accumulation of Lan-
gerhans cells [56]. Cigarette smoke also promotes survi-
val of dendritic cells, and induces the expression of the
anti-apoptotic B cell lymphoma leukemia-x(L) molecule
(Bcl-xL) [43], which has been shown to be over-
expressed in PLCH biopsies [57]. Taken together, these
data suggest a role for cigarette smoke as a direct stimu-
lant of airway factors that promote dendritic and Lan-
gerhans cell differentiation, activation and survival, and
Figure 1 Proposed pathogenesis of PLCH. The primary event in
the pathogenesis probably involves cigarette smoke-induced
recruitment and activation of Langerhans cells to the small airways,
a process that may result from a variety of potential mechanisms.
Cigarette smoke activates epithelial cells and macrophages to
produce cytokines and chemokines like granulocyte-macrophage
colony-stimulating factor (GM-CSF), Chemokine (C-C motif) ligand 20
(CCL20 or Macrophage Inflammatory Protein-3 alpha), transforming
growth factor-b (TGF-b), tumor necrosis factor-a (TNF-a) and
osteopontin that promote recruitment, retention and activation of
Langerhans cells. Cigarette smoke may also directly activate
Langerhans cells. Langerhans cells conditioned by cigarette smoke
may inappropriately recognize auto-antigens in the lungs and
activate adaptive T cell responses that secondarily mediate injury in
airway tissues. Chronic inflammation and cytokine production
(particularly TGF-b) may promote local fibroblast activation and
airway-centered fibrosis. The combination of airway centered
inflammation and tissue remodeling promote dilatation of structures
distal to the inflamed small airways and cystic formation. It is
possible, although not proven, that autoimmunity directed to
antigens expressed by epithelial or other lung cells, may promote
premature emphysema. Host genetic factors are likely to be very
important in disease development, while the potential role of
infection or other environmental factors could be relevant in the
induction of disease in some instances (although never proven).
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survival dendritic/Langerhans cell pathways.
The state of activation of lesional Langerhans cells is
one generally observed in the context of danger; patho-
logic Langerhans cells have potent lymphostimulatory
capacity and express abundant levels of costimulatory
molecules such as CD40, CD80 and CD86 [58,59]. Gen-
erally, activation of Langerhans cells results in changes
in surface chemokine receptors and migratory capacity,
which is meant to promote migration of activated Lan-
gerhans cells to secondary lymphoid structures. Why
activated Langerhans cells persist and form inflamma-
tory lesions in LCH is not known, but suggests that
migratory potential may be impaired. It is interesting to
note that dendritic cells incubated with cigarette smoke
extract express lower levels of the migratory chemokine
receptor CCR7, yet migrate with even greater efficacy
towards a CCR7 ligand in vitro when compared to con-
trol dendritic cells, suggesting that smoking-induced
suppression of CCR7 expression does not result in any
impairment of migratory capacity [43]. Although appar-
ent that cigarette smoke induces the production of cyto-
kines and chemokines that promote recruitment,
retention and activation of dendritic and Langerhans
cells around small airways, the putative mechanisms by
which the inflammatory cellular nodules promote small
airway remodeling and destruction of bronchiolar walls
remain incompletely characterized. Matrix metallopro-
teinases (MMPs) produced by dendritic, Langerhans and
other infiltrating monocytoid cells in inflammatory
nodules may play an important role in the airway remo-
deling and bronchiolar destruction observed in more
advanced disease. Tissue immunohistochemical studies
on PLCH biopsies have shown strong reactivity to
MMP2 and MMP9 particularly in the lesional dendritic
and Langerhans cells and macrophages, suggesting a
potential direct role for these cells in local airway remo-
deling [60,61].
A role for interleukin-17 (specifically IL-17A) as a
mediator of important cellular pathobiologic events per-
tinent to LCH has been proposed [62]. IL-17 is a cyto-
kine produced primarily by T cells, and has been
demonstrated to have an important role in host
responses to certain infections, vaccine responses, and
certain autoimmune diseases [63]. Coury et al. recently
showed that patients with active LCH have elevated
levels of circulating IL-17 [62]. More importantly, that
study showed that IL-17 is synthesized by lesional den-
dritic cells, and promotes fusion of dendritic cells to
form giant cells expressing tissue-destructive enzymes
[62]. Unfortunately, a separate investigative group was
unable to reproduce these findings [64], and the role of
IL-17 in the pathogenesis of LCH remains
indeterminate.
The effects of cigarette smoke on dendritic cell activa-
tion are complex and are best described as immunomo-
dulatory. Cigarette smoke induces inflammatory
dendritic cell responses directly by activating inflamma-
tory transcription factors. Dendritic cells incubated with
cigarette smoke extract produce inflammatory mediators
like CXCL8 and prostaglandin-E2 [65]. Cigarette smoke
also suppresses lipopolysaccharide and CD40-Ligand-
induced dendritic cell costimulatory molecule expression
and cytokine secretion [65-67].
A fundamental question pertaining to pathogenesis of
PLCH is whether the increased numbers of lesional Lan-
gerhans cells are associated with local proliferation of
the cells as opposed to another mechanism of accumula-
tion (such as enhanced recruitment and survival, or
delayed apoptosis). A study comparing the gene expres-
sion of cells expressing CD207 (a marker of Langerhans
cells) in systemic LCH lesions with control skin Langer-
hans cells showed no differences in genes regulating
proliferation, suggesting that LCH is a disorder of Lan-
gerhans cell accumulation and extended survival, rather
than local proliferation [55]. This is an important issue
because of the demonstration that lesional Langerhans
cells in both childhood and adult forms of multisystemic
LCH show biologic evidence of clonality, a process that
typically is associated with malignant processes and dys-
regulated proliferation [22]. Adult PLCH seems to be
different and studies on clonality in PLCH tissues have
not identified features of clonal proliferation [25], albeit
the techniques employed were quite different from the
studies involving pediatric biopsies that showed clonal-
ity. One may speculate that the smoking-induced form
of PLCH is a biologically distinct histiocytosis variant
that is more consistent with a reactive rather than a clo-
nal proliferative process. We propose that in contrast to
LCH involving other sites, tobacco-induced PLCH is a
reactive process incited by cigarette smoking in certain
predisposed individuals.
Gross pathology and histology
Gross inspection of the lung in PLCH may demonstrate
cystic structures on the surface, and upon sectioning,
nodules of varying sizes ranging from a few to 15 mm
in diameter may be observed [10,31]. In advanced dis-
ease, nodules may be absent, and the predominant find-
ing may be that of a hyperinflated lung with advanced
cystic changes [10]. In advanced cases, the gross appear-
ance may be difficult to distinguish from advanced
emphysema. Varying degrees of honeycombing may also
be present in the mid and upper lung fields [31]. The
upper and middle lung regions tend to be more severely
involved with disease, although advanced cystic change
and some degree of honeycombing may also be
observed in the lower lobes in advanced cases [31].
Suri et al. Orphanet Journal of Rare Diseases 2012, 7:16
http://www.ojrd.com/content/7/1/16
Page 4 of 13While PLCH has been traditionally classified as an
interstitial lung disease, in early stages, the predominant
pathology is that of an inflammatory and destructive
bronchiolitis with inflammatory cellular lesions of
loosely formed granuloma-like nodules distributed
around small airways [10,31,48]. Varying degrees of
interstitial inflammation may accompany these bronch-
iolocentric lesions [10,31]. Accumulation of pigmented
alveolar macrophages in small airways and distal air-
spaces is also very commonly seen [10,31]. In addition
to bronchiolar nodular inflammation and varying
degrees of alveolar macrophage infiltration, some cases
are associated with extensive vascular involvement
resulting in a vasculopathy that may be observed in
both arteries and veins [68]. The characteristic cystic
lesions form as the peribronchial lesions destroy the cel-
lular and connective tissue components of the bronchio-
lar walls, resulting in progressive dilatation of the
lumina of small airways which are eventually sur-
rounded by fibrous tissue [10,31,69]. This sequence of
events leads to the formation of bizarre shaped, irregular
parenchymal cystic lesions [69]. In addition, as seen in
other fibrotic disorders, traction emphysema of alveoli
adjacent to the stellate scars and peribronchial fibrotic
rings are commonly observed.
The microscopic appearance on lung biopsy speci-
mens varies depending on how advanced the disease
process is at the time of biopsy. The earliest lesions con-
sist of loose cellular nodules adjacent to small airways,
and scattered throughout the lung parenchyma forming
loosely-formed granulomas. These nodules are com-
posed of a mixed population of inflammatory cells,
including Langerhans cells and varying degrees of T-
lymphocyte, macrophage, plasma cell, monocyte and
eosinophilic infiltration [10,31]. The relative proportions
of the different inflammatory cell types vary greatly,
even in adjacent nodules in the same patient. The
bronchiolocentric lesions often form symmetric stellate
lesions with central scarring. Varying degrees of pigmen-
ted alveolar macrophage accumulation may be seen in
alveolar spaces causing a so-called “pseudo-desquama-
tive interstitial pneumonia” [10,31,32]. While in early
stage disease numerous cells accumulate adjacent to
terminal or respiratory bronchioles, resulting in destruc-
tion of the bronchiolar wall and the adjacent alveolar
structures, in more advanced disease, cellularity may
diminish considerably, and localized fibrotic changes
predominate [10,31].
The Langerhans cells found in the inflammatory nod-
ular lesions have pale, eosinophilic cytoplasm, and pos-
sess elongated nuclei with delicate folds and clefts
(Figure 2). In areas where lymphocytic infiltrates are
present, close contact may be observed between Langer-
hans cells and lymphocytes occur. Definitive
identification of Langerhans cells in the inflammatory
lesions is possible by the recognition of Birbeck granules
(pentalaminar rod-shaped intra-cellular structures) that
m a yb ev i s u a l i z e db ye l e c t r o nm i c r o s c o p yo rb yi m m u -
nohistochemical staining for Langerin (CD207)
[59,70,71]. Immunohistochemical staining for S-100 and
the CD1a antigen will show positivity on the cell sur-
face. While CD1a and S-100 stains are very helpful in
the identification of Langerhans cells, the mere presence
of these cells would not establish the diagnosis of
PLCH. Rather, there should be appropriate light micro-
scopic features including varying combination of nodu-
lar and cystic lesions with sizable aggregates of
Langerhans cells. An increased number of scattered
Figure 2 Light microscopy findings in PLCH. Upper panel shows
a low-power microscopic picture with nodular airway-centered
lesions showing microcystic change (20×, original magnification,
hematoxylin and eosin stain). The lower panel shows diffuse
infiltration of lung tissue with Langerhans cells showing vesicular
nuclear chromatin, irregular nuclear contour and moderate amount
of pale cytoplasm devoid of phagocytosed material. Many
eosinophils are also intermixed among Langerhans cells (200×
magnification, hematoxylin and eosin stain).
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lar parenchyma can be seen in a variety of other condi-
tions such as COPD, lung cancer and certain interstitial
lung diseases [72,73]. The histologic differential diagno-
sis includes other smoking-induced diffuse lung diseases
including respiratory bronchiolitis (a component of
which is almost always present in patients with PLCH),
desquamative interstitial pneumonia, and eosinophilic
pneumonia [31].
Diagnostic testing
Radiological findings
The chest radiograph (CXR) is almost always abnormal,
although the findings may be subtle and easy to over-
look [74,75]. Reticulonodular infiltrates are predominant
in early disease whereas cystic lesions are more domi-
nant in advanced disease [75]. Radiological changes in
advanced disease can be difficult to differentiate from
advanced cigarette smoke-induced emphysema [75].
Nodular or reticulonodular involvement is typically dif-
fuse, predominantly involving upper and middle lobes
with relative sparing of lung bases [75]. Lung volumes
on CXR are usually normal or increased [75].
High resolution chest CT (HRCT) should be obtained
in every patient as in many instances, it can distinguish
PLCH from other cystic lung diseases like lymphangio-
leiomyomatosis (LAM), Birt-Hogg- Dube syndrome, or
emphysema [19,20,76]. Several descriptive studies illus-
trate the utility of HRCT for delineating the nodules
and cysts that often have a characteristic distribution in
the upper and mid lung fields (Figure 3) [19,20,76].
HRCT provides radiographic correlates of pathologic
findings and provides important information regarding
the distribution of disease that may assist the surgeon in
choosing an optimal site for lung biopsy. Nodules (with
our without cavitation) measuring 1 to 10 mm in size
and favoring centrilobular location are often seen on
HRCT scans in early disease [20,76]. Pulmonary cysts,
although seen in any stage of disease, are more com-
monly found in more advanced disease [19,77]. The
cysts may have a thick or thin wall, and range in size
from a few millimeters to up to 20 mm. The HRCT pat-
tern of nodular and cystic changes involving upper and
middle lobes with relative sparing of lung bases results
i nah i g h l yc h a r a c t e r i s t i ca p p e a r a n c et h a to b v i a t e st h e
need for biopsy in some patients (Figure 3) [19,20,76].
While relative sparing of the lower lung fields is charac-
teristic in adults, chest CT imaging in pediatric PLCH is
almost always associated with involvement of the lower
lung zones and the costo-phrenic angles [18].
The management of LCH is highly influenced by dis-
ease extent (isolated pulmonary vs multi-systemic dis-
ease). A number of imaging tools may be used for
staging patients and determining the extent of disease.
Skeletal X-rays may determine the presence of bony dis-
ease, while gadolinium-enhanced Magnetic Resonance
Imaging of the brain is useful to determine potential
involvement of the pituitary/hypothalamic region or
other intracranial manifestations of LCH [78]. A rela-
tively recent imaging modality that is used to determine
the extent of disease burden is Fluorodeoxyglucose
-Positron Emission Tomography (FDG-PET) scanning
[79-81]. FDG-PET identifies active LCH lesions with a
higher sensitivity than computed tomography, and may
identify the presence of clinically occult disease in bone,
lung, lymph nodes, liver, thyroid and pituitary gland
[79-81]. Krajicek et al. recently published a retrospective
review of 11 patients with biopsy-proven PLCH in
whom FDG-PET was performed [81]; 5 patients demon-
strated positive findings which included foci of increased
uptake in nodular lung lesions and thick walled cysts,
increased uptake in mediastinal and hilar nodes, and
uptake in bony lesions. Positive FDG-PET findings were
more likely if the test was performed earlier in the clini-
cal course, in the context of predominantly nodular lung
lesions, and in patients with multiorgan involvement
[81]. Interestingly, many of the FDG-PET positive lung
nodules in PLCH patients were less than 8 mm, a size
threshold generally believed to preclude FDG-PET accu-
racy [81]. The role of FDG-PET in the assessment of
therapeutic intervention has also been explored. Phillips
and colleagues reported that FDG-PET scans can detect
LCH activity and early response to therapy with greater
accuracy than currently recommended imaging modal-
ities [79]. In that series of 44 patients (41 children, 3
Figure 3 Chest CT findings in PLCH. A) Coronal chest CT image
from a 36-year-old smoker with biopsy-proven PLCH demonstrating
a combination of large and small lung cysts and pulmonary
nodules, distributed predominantly in upper and mid-lung zones. B)
Chest CT section of a 35-year-old smoker with biopsy-proven PLCH
showing extensive bilateral upper lobe cystic lung changes and a
medium-sized pneumothorax in the right thoracic cavity. C) Chest
CT of a 40-year-old smoker with biopsy-proven PLCH showing a
combination of diffuse nodular and cystic abnormalities in both
lungs.
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of lesions and was rated superior in identifying new or
recurrent lesions [79]. That study also showed decreased
FDG uptake following therapy, and suggests a role for
FDG-PET as an objective tool to determine disease
response to therapy. Since the pulmonary nodules, and
some cystic lesions, frequently demonstrate standardized
uptake value (SUV) > 2.5, the test is not helpful in dis-
tinguishing inflammatory LCH lung lesions from a
malignant carcinoma (Figure 4) [81]. Until further pro-
spective data is available to guide the clinical use of
FDG-PET in the diagnosis and follow-up of LCH, rou-
tine use in all patients should not be encouraged. These
authors use FDG-PET as a modality to establish the
extent of disease in patients with substantial symptoma-
tology (include those with significant constitutional
symptoms), individuals with suspected extra-pulmonary
LCH, and to determine disease response following
chemotherapy.
Pulmonary function and echocardiographic findings
Pulmonary function test findings are variable depending
upon the course of the disease and prevalent anatomical
lesions [5,11]. Up to 20% of patients have normal pul-
monary function tests at the time of diagnosis [5,82].
Approximately 70% of patients have low diffusing capa-
city to carbon monoxide (DLCO), which is the most
common abnormality observed on physiologic testing
[5,82]. Reduction in DLCO may occur in isolation or
accompany restrictive, obstructive or mixed abnormality
and is primarily a reflection of pulmonary vascular
dysfunction [5,82]. A restrictive pattern is more fre-
quently observed in earlier stages of disease while an
obstructive pattern is more common as disease
advances, and is the predominant pattern as disease pro-
gresses [12,83]. A significant proportion of patients
develop progressive decline in DLCO and Forced
Expiratory Volume in 1 s (FEV1) within the first few
years following diagnosis, and develop severe airflow
obstruction [83]. Crausman and colleagues reported
either normal or restrictive physiology on lung function
testing in 23 patients with early disease [82]. In a study
including 102 adults, restriction was present in 46% of
cases at the time of diagnosis [5]. Although more than
90% of patients are smokers, obstruction is infrequently
attributed to smoking-related airway disease, as the
degree of obstruction seems out of proportion to cigar-
ette consumption indicating predominant small airways
or bronchiolar involvement. The exercise limitation in
patients with PLCH is largely attributed to vascular
impairment, at least in early disease [82]. In more
advanced disease, exercise limitation is frequently due a
combination of pulmonary vascular dysfunction and
ventilatory limitation.
Bronchoscopy and lung biopsy
Lung biopsy is required for definitive diagnosis of
PLCH. However it is possible to establish a provisional
diagnosis of almost definitive PLCH using less invasive
measures. Bronchoscopy with transbronchoscopic lung
biopsy (TBLB) will identify disease on lung biopsy in
approximately 15-40% of patients with established dis-
ease [84]. Bronchoalveolar lavage (BAL) should be per-
formed in all patients undergoing bronchoscopy, as the
detection of > 3% CD1a-positive cells (Langerhans’
cells) in the appropriate clinical context (supported by
consistent chest HRCT findings) is highly suggestive of
PLCH [40,41]. Although elevated numbers of CD1a
positive BAL cells is suggestive of PLCH, the clinician
needs to be aware of alternative lung diseases in which
increased BAL Langerhans cell numbers have also
been described [40,41,85]. Thus it is recommended
that quantitative assessment of BAL Langerhans cell
numbers be used for diagnostic purposes only when
the clinical features and radiographic findings are
highly suggestive of a diagnosis of PLCH. The identifi-
cation of 5% or greater CD1a positive BAL cells is
highly suggestive and probably diagnostic of PLCH,
but this degree of elevation of BAL Langerhans cells is
observed infrequently [40,41,85]. In many instances,
bronchoscopy and BAL do not provide diagnostic
information. If a definitive diagnosis is felt necessary,
surgical lung biopsy by video-assisted thoracoscopy or
open thoracotomy may be required. The chest HRCT
should be used to direct sites of biopsy, and multiple
Figure 4 PET findings in nodular PLCH. The chest CT images on
the left upper and lower panels show multiple lung nodules in a
smoker with surgical lung biopsy-proven PLCH. The corresponding
PET images on the right upper and lower panels show PET
characteristics of the multiple pulmonary nodules. The larger
pulmonary nodules (arrowhead) demonstrated intense PET uptake,
while other nodules (arrow) are PET-negative (Standardized Uptake
Value < 2.5).
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a greater diagnostic yield.
Clinical features, diagnostic approach and
management
About two-thirds of patients are symptomatic at presen-
tation [5]. Dyspnea and unproductive cough are the
most common symptoms at diagnosis [5,11]. Constitu-
tional symptoms, including fever, sweats, and weight
loss occur in 15-20% [5,11]. Chest pain usually signifies
pneumothorax or rib involvement. Pneumothorax
occurs in about 15% of patients [5]. Hemoptysis is
uncommon and is suggestive of alternative etiology such
as an acute bronchitis, bronchogenic carcinoma or
development of aspergilloma in a cystic cavity [5]. In
10-15% of adults diagnosed with PLCH, symptoms due
to extra-pulmonary disease may be present [5]. These
include polyuria and polydipsia due to diabetes insipi-
dus, pain which may be attributed to skeletal involve-
ment, or skin rashes due to cutaneous disease [5].
Establishing the diagnosis of PLCH requires a high
index of clinical suspicion. Although the presenting
symptoms, physical examination findings and laboratory
testing are generally non-specific, the lack of a current
or prior cigarette smoking history renders the diagnosis
of PLCH less likely. While chest radiography and pul-
monary function testing frequently show non-specific
findings, certain clinical contexts should alert the clini-
cian to consider PLCH. For instance, a history of cigar-
ette smoking and spontaneous or recurrent
pneumothorax should heighten consideration of PLCH
in any individual with bilateral indeterminate lung infil-
trates. Chest high resolution CT scanning should be
performed in all patients with indeterminate lung infil-
trates, particularly if there is history of cigarette smok-
ing. In many patients, the chest CT shows characteristic
findings consisting of nodular and cystic abnormalities
distributed principally in upper and middle lung zones
with relative sparing of the lower lung fields and costo-
phrenic angles. Although a biopsy is required to estab-
lish a definitive diagnosis, this may not be required or
necessary, particularly in mildly symptomatic patients
with “typical” radiologic findings in whom no specific
therapy is contemplated (other than smoking cessation).
When the chest CT shows findings that are non-diag-
nostic (nodular change without cysts, cystic changes
without nodularity, or involvement of lower lobes),
further evaluation with bronchoscopy or surgical lung
biopsy may be indicated to establish a definitive diagno-
sis. While the diagnostic yield of TBLB is relatively low
in establishing a definitive diagnosis [84], it may be
h e l p f u la sam e a n st oe v a l u a t ea l t e r n a t i v ed i a g n o s e s
such as sarcoidosis, hypersensitivity pneumonitis, infec-
tions such as Pneumocystis jirovecii pneumonia, or
LAM. A significant proportion of patients, particularly
those with unusual findings on the chest CT, or in
whom pharmacologic therapy is contemplated, may
require surgical lung biopsy for definitive diagnosis. In
addition, surgical lung biopsy may be required in
patients with imaging findings that demonstrate cavitary
nodules without cystic disease (differential including
cavitating metastatic tumors, septic emboli, pulmonary
granulomatosis with polyangiitis, mycobacterial and fun-
gal infection) or isolated cystic lung disease (differential
including LAM, Birt-Hogg-Dube syndrome, and the
recently described cystic lung induced by deposition of
light chain immunoglobulin [86]). In the patient with
documented extrapulmonary LCH (such as skin or
bone), a lung biopsy may not be required if the chest
CT shows features consistent with PLCH. In certain
cases that present at an advanced stage, chest imaging
and lung biopsy findings may be very difficult to distin-
guish from emphysema.
The specific management of children with PLCH will
not be discussed here, as pulmonary involvement in
children almost always occurs in the context of multi-
system disease which is managed with chemotherapy
protocols that have been subjected to relatively extensive
investigation through trials coordinated by the interna-
tional Histiocyte Society [26,27,87].
A critical component of the management of adults
with PLCH is smoking cessation. Smoking cessation
may lead to regression of disease or stabilization of
symptoms (Figure 5) [28,29], although some individuals
will have disease progression despite smoking cessation
[88]. There are no biological markers to predict which
patient will improve and who will continue to get worse
despite smoking cessation. Pharmacotherapy with
immunosuppressive medication should be considered
for all adult patients with severe disease, or patients in
whom progressive decline in lung function occurs. Cor-
ticosteroids in the form of prednisone 0.5-1.0 mg/kg
daily with slow tapering over months have historically
been employed to treat patients with progressive disease,
but it remains unclear as to whether patients objectively
respond to corticosteroid therapy [11,12]. Other immu-
nosuppressive agents, including chlorodeoxyadenosine
(also known as cladribine or 2-CDA), cyclophospha-
mide, and methotrexate, have been used to treat pro-
gressive disease [89-92]. Chlorodeoxyadenosine is a
purine analogue shown to be directly toxic to mono-
cytes [93]. Cladribine has been used in the management
of multi-system LCH involving bone and skin with up
to 75% response rate [90,91,94], but its utility in the
management of isolated smoking-induced PLCH is not
well-defined, and requires further investigation. Therapy
with cladribine has been reported to induce remission
or improvement in lung lesions in a number of cases of
Suri et al. Orphanet Journal of Rare Diseases 2012, 7:16
http://www.ojrd.com/content/7/1/16
Page 8 of 13PLCH, and is a promising candidate for future trials
[92,94,95]. Whether immunosuppressive or cytotoxic
therapy is effective in the management of patients with
progressive disease who continue to smoke is not
known.
Spontaneous pneumothorax can be an initial manifes-
tation in approximately 15% of patients and seems to be
more frequent in younger patients [5,96]. Pneumothorax
is usually unilateral, although rare cases of spontaneous
bilateral pneumothoraces have been reported [97].
Recurrence is usually ipsilateral but can occur in con-
tralateral lung. Pulmonary function parameters and sur-
vival are usually similar in patients with or without
pneumothorax. Whether therapy with corticosteroids or
chemotherapeutic agents reduces the rate of pneu-
mothorax is unknown. Small pneumothoraces may be
managed conservatively. Surgical management is recom-
mended for any patient with recurrent pneumothorax,
or a single moderate to large pneumothorax, since the
rate of recurrence with a conservative approach (chest
tube drainage without pleurodesis) is unacceptably high.
In one study, a recurrence rate of 58% was reported
when pneumothorax was treated with either observation
or chest tube alone; in contrast there were no recur-
rences when managed surgically with a mechanical
pleurodesis [96]. Pleurodesis does not preclude from
lung transplantation, which should be considered in
patients with progressive lung disease.
Pulmonary hypertension is a common and under-
recognized complication. It is increasingly appreciated
that the incidence and severity of pulmonary hyperten-
sion in PLCH is higher than that observed in other
chronic lung diseases such as idiopathic pulmonary
fibrosis, and is associated with poor survival [68,98,99].
Retrospective studies have failed to show correlation
between the severity of pulmonary hypertension and
impairment in pulmonary function parameters, except
for one study showing an inverse relation with forced
vital capacity [99]. In contrast to other chronic lung dis-
eases, the pulmonary hypertension in PLCH is asso-
ciated with a primary pulmonary vasculopathy, which
may be observed histopathologically as intimal fibrosis
and remodeling of both venous and arterial systems
[68]. Progressive vascular involvement may occur in a
minority of patients despite relative stability of pulmon-
ary parenchymal lesions. Due to prognostic and poten-
tial therapeutic implications (personal observations), it is
important to screen all patients for pulmonary hyperten-
sion. Although there is no universally accepted screen-
ing test for pulmonary hypertension, echocardiography
is very useful in this context and provides a noninvasive
approach to screen patients [99]. Our practice is to
screen all patients at the time of diagnosis, particularly
patients with dyspnea that seems to be out of propor-
tion to degree of pulmonary function impairment. In
patients with echocardiographic signs of possible pul-
monary hypertension (elevated estimated right ventricu-
lar systolic pressure > 40 mmHg, or reduced right-sided
cardiac function) it is prudent to consider cardiac cathe-
terization with the goal of confirming the presence,
defining the severity of pulmonary hypertension, and
objectively determining the hemodynamic response to a
vasodilator trial. When pulmonary hypertension is pre-
sent, therapy with vasodilators including phosphodies-
terase inhibitors or endothelin receptor antagonists may
be of substantial benefit, and may result in objective
reduction in pulmonary artery pressure and improved
exercise capacity (unpublished observations). Epoproste-
nol (prostacyclin) can cause severe pulmonary edema
and should be used very cautiously in this patient popu-
lation given the prominent venous involvement and
higher incidence of veno-occlusive disease [68,100]. In
addition to appropriate trials of vasodilator therapy,
patients with moderate to severe pulmonary hyperten-
sion may benefit from anticoagulation and supplemental
oxygen to correct underlying hypoxemia.
Figure 5 Radiographic improvement following smoking
cessation. The chest CT images on the left side were performed in
an active one pack/day 37 year old smoker with biopsy-proven
PLCH. The representative chest CT images demonstrate diffuse
nodular infiltrates in both upper and lower lung fields. The patient
quit smoking 2 months after the first chest CT was performed. The
representative chest CT images on the right side were performed
one year after the first chest CT was obtained, and show
considerable improvement in the nodular infiltrates following
smoking cessation. The patient did not receive corticosteroid or
other immunosuppressive therapy.
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number of patients with progressive disease despite
smoking cessation and a trial of immunosuppressive
therapy. It should be considered in patients with severe
respiratory impairment refractory to other forms of
treatment, including patients with progressive pulmon-
ary hypertension unresponsive to vasodilator therapy.
Pleurodesis should not preclude from lung transplanta-
tion. Pulmonary hypertension is noted in the majority
(90%) of patients at the time of transplant evaluation
and may increase the risk of surgery [101]. Post trans-
plant survival data are similar to those reported for
other lung diseases treated with transplantation, includ-
ing cystic fibrosis and emphysema. Post-transplant com-
plications are also similar to transplant for other
indications. In a retrospective study of 39 patients, 15
received single lung transplantation, 15 double lung
transplantation and 9 heart-lung transplantation [101].
Post transplant survival was 76% at 1 year and 54% at
10 years [101]. Extra-pulmonary involvement was pre-
sent in 31% of the patients and was associated with
higher recurrence [101]. The association between smok-
ing and disease recurrence was questioned by that study
[101]. Transplant type, extra-thoracic involvement or
recurrence had no impact on the survival [101]. Inci-
dence of post transplant bronchiolitis obliterans syn-
drome or acute rejection was similar to transplant for
other indications.
Outcomes and prognosis
The course of PLCH in adults is variable and unpredict-
able, ranging from asymptomatic to progressive debili-
tating disease that leads to respiratory failure and death
over a period of few years. The survival of adults with
established PLCH is shorter than that in the general
population [5]. Several factors have been associated with
poor outcome including extremes of age, prolonged
constitutional symptoms, multi-organ involvement,
extensive cysts and honeycombing on the radiograph,
severely reduced diffusing capacity, obstructive physiol-
ogy on lung function testing, prolong treatment with
steroid therapy and associated pulmonary hypertension
[5,102]. None of these criteria, except the presence of
pulmonary hypertension, can reliably predict prognosis
in the individual patient [99]. Respiratory failure
accounts for a substantial proportion of deaths in end-
stage disease [5]. It is very difficult to determine how
many patients progress to respiratory failure since a pro-
portion of these patients have associated emphysema
due to long-standing tobacco abuse. Patients with PLCH
have an increased incidence of secondary malignancies,
including lymphoma and other hematological malignan-
cies [5,103-105]. Whether the increased incidence of
hematological malignancies represents a stem cell defect
in cells of hematological lineage, chemotherapy-induced
long-term toxicity, or a tobacco effect is unknown.
Unresolved issues and future directions
While substantial progress has been made, many issues
remain unresolved with respect to pathogenesis, disease
characterization, sub-classification, clinical evaluation,
and management of adults with PLCH. The relationship
between cigarette smoke exposure and disease progres-
sion or regression remains to be definitively character-
ized. While there are many insights into potential
mechanisms by which smoking may promote PLCH in
certain individuals, many aspects of pathogenesis remain
unclear. The roles of lymphocytes and eosinophils that
populate many of the inflammatory nodular lesions
remain unclear. The role of clonality in PLCH, and the
potential implications of its identification, remains
incompletely characterized. Future studies should
address important questions regarding therapy, includ-
ing the roles and use of chemotherapy in individuals
with progressive lung disease and the role of pulmonary
vasodilator therapy in patients with pulmonary hyper-
tension. The complex nature of the disease and its rarity
tend to promote delays in diagnosis and therapy, fre-
quently leading to patient frustration and the sensation
of being “orphans” without dedicated medical providers.
To this end, voluntary patient advocacy organizations
have provided important contributions by facilitating
referral to medical practitioners with expertise and
interest in the management of histiocytic diseases. The
care of patients with PLCH requires a multi-disciplinary
approach with relevant interactions of medical (Pulmon-
ary, Hematology/Oncology, Cardiology, and Dermatol-
ogy) and surgical specialists. Co-operative efforts
between physicians, scientists and patient advocacy
groups may enable the design of prospective treatment
trial that may ultimately improve the life expectancy
and quality of life of patients with PLCH.
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